Product New February 2010

Synovis Life Technologies to Distribute MicroClip™ Globally

     Synovis Life Technologies Inc (St. Paul, Minn), a biomaterial and surgical products company recently announced that its wholly owned subsidiary, Synovis Micro Companies Alliance Inc (Synovis MCA) has received exclusive worldwide distribution rights to sell the GEM™ SuperFine™ MicroClip™. The new product is the smallest clip on the market that is specially designed to stop bleeding during surgical procedures. Microsurgeons will use the clip in various specialties such as, plastic and reconstructive, head and neck, orthopedic and hand, in procedures ranging from breast reconstruction to tissue grafts following cancer surgery and the reattachments or repair of fingers and limbs.      The clip keeps pace with changing needs in the microsurgical market and furthers Synovis MCA’s goal of serving as “The Microsurgeon’s Most Trusted Resource™.” The clip is made of pure, annealed titanium for a malleable consistency that allows for zero memory, which prevents the tip from opening after application. The clip is biologically inert and the non-ferrous titanium is safe for use with MRI or related scanning equipment. The unique chevron shape of the clip provides progressive and encompassing tip-to-tip closure for secure vessel occlusions. The diamond shape grooving and interlocking atraumatic teeth on the clip’s inner surface ensure a firm multi-direction non-crushing grip. Additionally, the ergonomically de-signed cartridge includes an adhesive backing for precise and effortless clip loading.      Visit www.synovislife.comfor more information.

Cardium Launches MedPodium™ Podiatry Product Line

     Cardium Therapeutics (San Diego, Calif) plans to launch a new premium advanced skin care product line to promote foot health and comfort for podiatry patients. The company’s new MedPodium™ product line is an over-the-counter product portfolio for patients with the potential for foot disorders and ailments. MedPodium represents a new line of foot care products to broaden and complement the company’s Excellagen topical gel product candidate platform, which is currently subject to a pending FDA 510(k) application submission for US marketing clearance for the management of wounds including partial- and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, surgical wounds, and certain other wounds. The patient care podiatric product line has been designed to promote foot health and comfort and support preventative care, self examination and early detection of foot ulcers, especially for patients with diabetes and lower extremity neuropathy. Daily use of the natural crèmes and gels are intended to assist self-examination and early detection of foot ulcers, which can potentially become a serious and chronic medical problem that can contribute to increased morbidity and mortality without proper care and early treatment, particularly for patients with diabetes.      Visit www.cardiumthx.comfor more information.